Johnson & Johnson Net Profit Margin 2006-2021 | JNJ

Current and historical net profit margin for Johnson & Johnson (JNJ) from 2006 to 2021. Net profit margin can be defined as net Income as a portion of total sales revenue. Johnson & Johnson net profit margin for the three months ending September 30, 2021 was .
Johnson & Johnson Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2021-09-30 $91.45B $17.88B 19.55%
2021-06-30 $89.19B $17.77B 19.92%
2021-03-31 $84.21B $15.12B 17.95%
2020-12-31 $82.58B $14.71B 17.82%
2020-09-30 $80.86B $16.99B 21.01%
2020-06-30 $80.50B $15.19B 18.86%
2020-03-31 $82.73B $17.17B 20.75%
2019-12-31 $82.06B $15.12B 18.42%
2019-09-30 $81.71B $14.15B 17.32%
2019-06-30 $81.33B $16.33B 20.08%
2019-03-31 $81.59B $14.68B 17.99%
2018-12-31 $81.58B $15.30B 18.75%
2018-09-30 $81.38B $1.54B 1.89%
2018-06-30 $80.68B $1.37B 1.70%
2018-03-31 $78.69B $1.25B 1.58%
2017-12-31 $76.45B $1.30B 1.70%
2017-09-30 $74.36B $15.83B 21.28%
2017-06-30 $72.53B $16.34B 22.52%
2017-03-31 $72.17B $16.51B 22.87%
2016-12-31 $71.89B $16.54B 23.01%
2016-09-30 $71.60B $15.94B 22.27%
2016-06-30 $70.88B $15.03B 21.20%
2016-03-31 $70.18B $15.55B 22.15%
2015-12-31 $70.07B $15.41B 21.99%
2015-09-30 $70.52B $14.72B 20.87%
2015-06-30 $71.88B $16.11B 22.41%
2015-03-31 $73.59B $15.92B 21.63%
2014-12-31 $74.33B $16.32B 21.96%
2014-09-30 $74.43B $17.32B 23.27%
2014-06-30 $73.54B $15.55B 21.15%
2014-03-31 $71.92B $15.06B 20.94%
2013-12-31 $71.31B $13.83B 19.40%
2013-09-30 $70.52B $12.88B 18.26%
2013-06-30 $69.99B $12.87B 18.38%
2013-03-31 $68.59B $10.44B 15.22%
2012-12-31 $67.22B $10.85B 16.14%
2012-09-30 $65.92B $8.50B 12.90%
2012-06-30 $64.87B $8.74B 13.47%
2012-03-31 $65.00B $10.11B 15.55%
2011-12-31 $65.03B $9.67B 14.87%
2011-09-30 $64.42B $11.40B 17.69%
2011-06-30 $63.40B $11.61B 18.32%
2011-03-31 $62.13B $12.28B 19.77%
2010-12-31 $61.59B $13.33B 21.65%
2010-09-30 $62.49B $13.60B 21.76%
2010-06-30 $62.59B $13.53B 21.61%
2010-03-31 $62.50B $13.29B 21.26%
2009-12-31 $61.90B $12.27B 19.82%
2009-09-30 $60.53B $12.77B 21.10%
2009-06-30 $61.37B $12.74B 20.76%
2009-03-31 $62.58B $12.86B 20.55%
2008-12-31 $63.75B $12.95B 20.31%
2008-09-30 $64.52B $12.61B 19.54%
2008-06-30 $63.57B $11.85B 18.64%
2008-03-31 $62.25B $11.60B 18.64%
2007-12-31 $61.10B $10.58B 17.31%
2007-09-30 $58.82B $10.37B 17.63%
2007-06-30 $57.14B $10.58B 18.52%
2007-03-31 $55.37B $10.32B 18.64%
2006-12-31 $53.32B $11.05B 20.73%
2006-09-30 $52.25B $10.98B 21.01%
2006-06-30 $51.28B $10.76B 20.98%
2006-03-31 $50.67B $10.53B 20.77%
2005-12-31 $50.51B $10.06B 19.92%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $430.061B $82.584B
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Stock Name Country Market Cap PE Ratio
Pfizer (PFE) United States $290.297B 13.76
Novo Nordisk (NVO) Denmark $259.405B 34.32
Eli Lilly (LLY) United States $234.470B 29.08
AbbVie (ABBV) United States $214.730B 9.87
Merck (MRK) United States $182.575B 12.51
Novartis AG (NVS) Switzerland $180.460B 12.99
GlaxoSmithKline (GSK) United Kingdom $114.112B 13.90